Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 6, 2025JCO Precision Oncology

Impact of BRCA Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Breast Cancer: A Systematic Review and Meta-Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

HAHamdy A. AzimHEHagar ElghazawyKSKyrillus S. Shohdy

Discussion

Loading...

Member takes

Overview

Systematic review reveals brca mutation worsens OS and PFS in hormone receptor-positive breast cancer, indicating unique treatment challenges.

Key Points

  • BRCA mutation is linked to worse overall survival (OS) and progression-free survival (PFS) in hormone receptor-positive breast cancer.
  • Meta-analysis included 22 studies, totaling 34,960 patients with varying outcomes based on BRCA mutation status.
  • BRCA1/2 mutant patients showed significantly poorer prognosis compared to wild-type, especially when treated with endocrine therapy plus CDK4/6 inhibitors.
  • The findings suggest a unique resistance of BRCA2 mutants to therapy, emphasizing the need for targeted approaches in treatment.

Cite This Study

Azim et al. (2025) studied this question.

synapsesocial.com/papers/689a0fa0e6551bb0af8d18e2https://doi.org/10.1200/po-24-00841
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer2024 · 10 citations
  2. 2A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer2016 · 170 citations
  3. 3BRCA1/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma2022 · 36 citations
  4. 4Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer2022 · 24 citations
  5. 5Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer2018 · 1,317 citations